---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000171"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:21:32.350497+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q3 revenue $37M (+58% YoY), raises 2022 guidance to $132-137M

## Summary
- Q3 revenue $37.0M (+58% YoY); total test reports 12,114 (+57% YoY).
- Net loss $(20.2)M vs $(11.8)M; adjusted EBITDA $(8.3)M vs $(5.5)M.
- 2022 revenue guidance raised to $132-137M from $130-135M.
- Three-year target: FY2025 revenue $255-330M; positive net operating cash flow by 2025.
- Acquisitions TissueCypher (690 reports) and IDgenetix (1,208 reports) contributed in Q3.

## SEC filing metadata
- accession: 0001447362-22-000171
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/cstl-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000171
- JSON: https://secwatch.observer/filing/0001447362-22-000171.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000171.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the third quarter ended September 30, 2022 results: revenue $37.0 million, net income $(20.2) million. Guidance raised.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $37.0 million
  - Net income: $(20.2) million
  - Guidance: raised
  - Result: reported results
  source text: Revenues were $37.0 million, a 58% increase compared to $23.5 million during the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm
- Earnings Releases
  CASTLE BIOSCIENCES INC reported the nine months ended September 30, 2022 results: revenue $98.7 million, net income $(46.5) million. Guidance raised.
  - Period: the nine months ended September 30, 2022
  - Revenue: $98.7 million
  - Net income: $(46.5) million
  - Guidance: raised
  - Result: reported results
  source text: Revenues were $98.7 million, a 43% increase compared to $69.0 million during the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000171/0001447362-22-000171-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.